DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report issued on Monday. The firm set a “hold” rating on the stock.

A number of other research firms also recently commented on DBVT. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of DBV Technologies in a report on Thursday, August 1st. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 target price on shares of DBV Technologies in a report on Tuesday, September 24th.

DBV Technologies Stock Performance

Shares of NASDAQ DBVT opened at $0.71 on Monday. The company has a market cap of $68.04 million, a PE ratio of -0.84 and a beta of 0.67. The business has a 50-day simple moving average of $0.79 and a two-hundred day simple moving average of $0.97. DBV Technologies has a fifty-two week low of $0.50 and a fifty-two week high of $2.28.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.08). DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. The business had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.42 million. During the same period in the prior year, the business posted ($0.26) EPS. On average, sell-side analysts predict that DBV Technologies will post -1.43 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. boosted its stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the quarter. DBV Technologies accounts for 0.2% of Yiheng Capital Management L.P.’s holdings, making the stock its 15th largest position. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.